中药对改善介入治疗肝癌患者凝血纤溶功能紊乱情况的研究  

Study on TCM Improving Cruor-fibrinolysis Disorders of Liver Cancer Patients Given with Interventional Therapy

作　　者：卢冠铭[1] 黄照权[1] 梁烨[1] 李天资[1] 陈永诚[1] 陆高翔[1] 蓝家富[1] 李清锋[1] 

机构地区：[1]右江民族医学院临床学院腺体外科,广西百色533000

出　　处：《西部中医药》2013年第7期1-4,共4页Western Journal of Traditional Chinese Medicine

基　　金：国家自然科学基金(编号81060028);广西科技攻关计划基金(编号桂科攻1355005-3-7);广西卫生厅科学基金(编号Z2010092;Z2010474;Z2010086)

摘　　要：目的:探讨中药改善介入治疗肝癌患者凝血纤溶紊乱功能的情况。方法:给予介入治疗的20例原发性肝细胞癌(HCC)患者中药治疗,于治疗前后检测患者血浆凝血酶原时间(PT)、部分凝血活酶时间(APTT)、凝血酶时间(TT)、纤维蛋白原含量(FIB)、P-选择素(Ps)、血管性血友病因子(vWF)、尿激酶型纤溶酶原激活物(uPA)和检测纤溶酶原激活物抑制物(PAI)水平,并与单纯介入治疗的20例原发性肝细胞癌(HCC)和10例健康组比较。结果:与治疗前比较,治疗组患者PT、APTT、TT和FIB水平均有好转(P<0.01或P<0.05),对照组PT、APTT、TT和FIB水平均无好转(P>0.05);治疗后与健康组比较,治疗组患者PT、APTT、TT和FIB水平已经达到正常组的平均水平(P>0.05),对照组PT、APTT、TT和FIB水平均未达到正常组的平均水平(P<0.01)。与治疗前比较,治疗组患者Ps、vWF、uPA和PAI水平均有好转(P<0.05),对照组uPA水平有好转(P<0.01);治疗后与健康组比较,治疗组患者Ps、vWF和PAI水平已经达到正常组的平均水平(P>0.05),对照组Ps、vWF、uPA和PAI水平均未达到正常组的平均水平(P<0.01或P<0.05)。结论:中药可改善介入治疗HCC患者凝血纤溶功能紊乱,预防血栓形成,促进康复。Objective： To explore the state of TCM improving cruor-fibrinolysis disorders of liver cancer patients who received interventional therapy. Method： Twenty patients with hepatocellular carcinoma （HCC） who received interventional therapy took herbs. Plasma prothrombin time （PT）, partial thromboplastin time （APTT）, thrombin time（TT）, the contents of fibrinogen（FIB）, P-selectin （Ps）, von willebrand factor （vWF）, urokinase-type plasminogen activator （uPA） and level of plasminogen activator inhibitor （PAI） were tested before and after the treatment, those indexes were compared with those of twenty patients received single interventional therapy and ten cases in the healthy group. Result： The levels of PT, APTT, TT and FIB of the patients in the treatment group were improved compared with those before treating （P〈0.01 or P〈0.05）, the levels of PT, APTT, TT and FIB in the patients of the control group were unchanged （P〉0.05）; PT, APTT, TT and FIB of the patients after treating have reached to the average levels of the normal group compared with the healthy group （P〉0.05）, those indexes of the patients in the control group haven＇t been to average levels of the normal group （P〈0.01）. The levels ofPs, vWF, uPA and PAI of the patients in the treatment group were improved compared with those before treating（P〈0.05）, the level ofuPA of the control group was improved（P〈0.01）. Compared with the healthy group, Ps, vWF and PAI of the patients of the treatment group have already been to average level of the normal group （P〉 0.05）, those indexes of the control group haven＇t been to average levels of the normal group （P〈0.01 or P〈0.05）. Conclusion： TCM could improve the cruor-fibrinolysis disorders of liver cancer patients who received interventional therapy, effectively prevent the thrombogenesis and promote the rehabilitation.

关 键 词：肝细胞癌 原发性 血栓前状态 中药治疗 

分 类 号：R735.7[医药卫生—肿瘤]